Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease …

The prevalence of atrial fibrillation (AF) is increasing as the population ages. AF treatment-
related complications also increase markedly in older adults (defined as≥ 75 years of age …

Aims Atrial fibrillation (AF) is the most common arrhythmia and prevalence increases with
age. Patients with AF have a high risk of stroke, and screening for AF is recommended in all …

Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and
mortality resulting from cardioembolic stroke. Oral anticoagulation therapy has been shown …

Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines
as the first-line option for the treatment of venous thromboembolism and prevention of stroke …

Background Four direct oral anticoagulants (DOACs) have been approved for clinical use by
many medicines regulatory agencies around the world. Due to increasing use of these drugs …

Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the most common
arrhythmia leading to hospitalization. Due to a substantial increase in incidence and …

Importance In atrial fibrillation (AF)–related acute ischemic stroke, the optimal oral
anticoagulation strategy remains unclear. Objective To test whether rivaroxaban or warfarin …